$BLCO

VON ESCHENBACH ANDREW C. sold $307K of BLCO

VON ESCHENBACH ANDREW C. sold 18,559 shares of Bausch & Lomb Corp (BLCO) at an average of $16.53 ($16.50–$16.58, $0.31M total) across 2 trades over 2026-08-06 to 2026-08-07.

Original reporting
SEC EDGAR · VON ESCHENBACH ANDREW C.
Published Aug 11, 2026, 12:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLCO
Neutral
low confidence
Mentioned
$BLCO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLCONeutralLow
01

Why it matters

The only new fact is the reported sale size, price range, and post-transaction holdings; it does not include guidance, earnings, litigation, or operational updates.

02

Market read

Traders may monitor insider selling as a sentiment input, but this filing alone is unlikely to change valuation without accompanying fundamentals.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing lacks any explanation for motive.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-10, covering sales dated 2026-08-06 to 2026-08-07

Background

The article is an SEC Form 4 insider transaction for Bausch & Lomb Corp, reporting an open-market sale by a director.

Company-level read

Ticker impact

$BLCONeutralLow confidence
Context

Bausch & Lomb director Andrew C. Von Eschenbach sold 18,559 shares in open-market transactions at about $16.50 to $16.58.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

Form 4 insider sales are common and the filing provides no new company-specific operational or financial information.

Market effects

Minimal, as the disclosure is company-specific insider activity without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the article notes no pre-arranged 10b5-1 plan, some traders may interpret the sale as higher conviction than typical, potentially adding short-term downside pressure.

Key entities

  • Bausch & Lomb Corp

    Subject of the Form 4 insider transaction disclosure.

  • Andrew C. Von Eschenbach

    Director who sold 18,559 shares in two open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BLCOMedAI 8/10

What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call

Bausch + Lomb (BLCO) reported Q3 earnings, highlighting growth across multiple franchises. Adjusted gross margin rose to 64.7%, with operating cash flow at $233M. The company raised its 2026 revenue outlook to $5.45B-$5.55B and adjusted EBITDA guidance to $1.09B-$1.14B. Interim CEO Appio focused on profitability and R&D pipeline advancements.

$BLCOHighAI 8/10

Bausch & Lomb Corp (BLCO) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth

Bausch & Lomb Corp (BLCO) reported Q3 2026 revenue growth of 8%, with all segments showing gains. Adjusted EBITDA rose 34% to $325M. The company raised full-year revenue and EBITDA guidance. Key products like MIBO and Lumify saw strong growth, while surgical equipment revenue declined 11%. The company faces regulatory and competitive pressures. Leadership changes were announced, with Tom Appio becoming interim CEO.

$BLCOHighAI 8/10

Bausch + Lomb Soars 16% on Big Q3 Profit Beat and Raised Full-Year Guidance

Bausch + Lomb's shares rose 16% after Q3 earnings beat expectations, with adjusted EPS at $0.34 vs. $0.22 consensus and revenue up 7% to $1.375B. Adjusted EBITDA increased 34% to $325M, and the company raised its full-year EBITDA guidance by $65M. Key growth drivers included MIEBO, LUMIFY, and premium intraocular lenses. Johnson & Johnson's contact lens sales also grew, contrasting with Cooper Companies' flat sales.

$BLCOMed

Bausch + Lomb: Q3 Earnings Snapshot

Bausch + Lomb (BLCO) reported Q3 net income of $32M, or 9 cents per share, beating estimates. Adjusted EPS was 34 cents. Revenue was $1.38B, also topping forecasts. The company expects full-year revenue of $5.45B-$5.55B. Shares are up 14% YTD and 26% over 12 months.